

Stefan Boeck

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/9617341/publications.pdf](https://exaly.com/author-pdf/9617341/publications.pdf)

Version: 2024-02-01

86
papers

4,523
citations

100698

35
h-index

103468

64
g-index

102
all docs

102
docs citations

102
times ranked

7476
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in cancer immunotherapy 2019 – latest trends. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 268.	8.9	432
2	Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. <i>BMC Cancer</i> , 2008, 8, 82.	2.6	379
3	Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. <i>Cancer Medicine</i> , 2016, 5, 2649-2656.	2.9	207
4	Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. <i>Cancer Treatment Reviews</i> , 2009, 35, 262-271.	8.0	186
5	Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2018, 155, 1625-1639.e2.	1.4	156
6	Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. <i>European Journal of Internal Medicine</i> , 2018, 49, 44-50.	2.2	152
7	Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. <i>Journal of Clinical Oncology</i> , 2013, 31, 4453-4461.	5.4	151
8	Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. <i>Nature</i> , 2023, 615, 168-174.	35.8	143
9	Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 681-689.	2.6	128
10	Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. <i>Annals of Oncology</i> , 2018, 29, 2348-2355.	1.3	122
11	Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. <i>Oncotmmunology</i> , 2017, 6, e1310358.	4.7	118
12	Systemic treatment of advanced pancreatic cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 843-853.	8.0	109
13	Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the –Arbeitsgemeinschaft Internistische Onkologie–™ (AIO-PK0104). <i>Gut</i> , 2013, 62, 751-759.	13.5	108
14	Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. <i>Annals of Oncology</i> , 2013, 24, 2484-2492.	1.3	102
15	EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. <i>British Journal of Cancer</i> , 2013, 108, 469-476.	6.5	85
16	Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. <i>Annals of Oncology</i> , 2008, 19, 340-347.	1.3	71
17	Importance of performance status for treatment outcome in advanced pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2007, 13, 224.	3.4	70
18	KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. <i>Journal of Gastroenterology</i> , 2013, 48, 544-548.	5.1	68

#	ARTICLE	IF	CITATIONS
19	Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. <i>Annals of Oncology</i> , 2007, 18, 745-751.	1.3	62
20	Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. <i>Surgery</i> , 2015, 158, 151-161.	2.0	59
21	Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. <i>Pancreatology</i> , 2016, 16, 593-598.	1.8	59
22	Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 404-415.	11.3	59
23	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , 2018, 19, e151-e160.	10.7	55
24	Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer – A retrospective cohort study. <i>Thrombosis Research</i> , 2017, 157, 9-15.	1.7	52
25	Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2013, 108, 1684-1694.	6.5	50
26	Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: A Retrospective Cohort Study. <i>International Journal of Surgery</i> , 2016, 28, 118-125.	3.6	49
27	Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNase in patients with advanced pancreatic cancer undergoing chemotherapy. <i>International Journal of Cancer</i> , 2013, 133, n/a-n/a.	5.4	48
28	Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. <i>Tumor Biology</i> , 2010, 31, 351-357.	1.7	46
29	Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. <i>European Journal of Cancer</i> , 2014, 50, 1855-1863.	2.9	46
30	Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 986-994.	7.2	43
31	Medicinal plants used by the people of Nsukka Local Government Area, south-eastern Nigeria for the treatment of malaria: An ethnobotanical survey. <i>Journal of Ethnopharmacology</i> , 2018, 218, 1-15.	4.2	40
32	Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the Arbeitsgemeinschaft Internistische Onkologie™. <i>European Journal of Cancer</i> , 2018, 94, 95-103.	2.9	33
33	Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. <i>European Journal of Cancer</i> , 2014, 50, 1891-1899.	2.9	32
34	pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. <i>BMC Cancer</i> , 2014, 14, 624.	2.6	29
35	Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2585-2591.	2.6	29
36	RO resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007A± trial. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 8-18.	2.2	29

#	ARTICLE	IF	CITATIONS
37	Erlotinib 150mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the "Arbeitsgemeinschaft Internistische Onkologie"™. <i>Anti-Cancer Drugs</i> , 2010, 21, 94-100.	1.4	28
38	Clinical outcome of elderly patients (≥70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis. <i>Radiation Oncology</i> , 2018, 13, 93.	2.7	27
39	Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 1462-1469.	6.5	26
40	Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 355-360.	5.9	24
41	Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the "burden of therapy"™ method. <i>European Journal of Cancer</i> , 2021, 146, 95-106.	2.9	21
42	Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients. <i>Bone Marrow Transplantation</i> , 2006, 37, 57-64.	2.4	20
43	Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. <i>British Journal of Cancer</i> , 2016, 115, 1520-1529.	6.5	20
44	The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1094.	4.2	20
45	Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts. <i>World Journal of Gastroenterology</i> , 2014, 20, 10769.	3.4	20
46	Dosing to rash? " The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. <i>European Journal of Cancer</i> , 2016, 55, 131-139.	2.9	19
47	Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2007, 18, 1109-1111.	1.4	18
48	The Role of Second-Line Chemotherapy After Gemcitabine Failure In Patients With Advanced Pancreatic Cancer. <i>Future Oncology</i> , 2008, 4, 41-50.	2.4	18
49	POLE gene hotspot mutations in advanced pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2161-2166.	2.6	16
50	Surgical treatment concepts for patients with pancreatic cancer in Germany" results from a national survey conducted among members of the "Chirurgische Arbeitsgemeinschaft Onkologie" (CAO) and the "Arbeitsgemeinschaft Internistische Onkologie" (AIO) of the Germany Cancer Society (DKG). <i>Langenbeck's Archives of Surgery</i> , 2011, 396, 223-229.	1.9	15
51	Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 391-399.	2.6	15
52	Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2014, 25, 1095-1101.	1.4	14
53	Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3. <i>Tumor Biology</i> , 2015, 36, 2631-2640.	1.7	13
54	Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study. <i>ESMO Open</i> , 2022, 7, 100388.	4.3	13

#	ARTICLE	IF	CITATIONS
55	Novel systemic treatment approaches for metastatic pancreatic cancer. Expert Opinion on Investigational Drugs, 2022, 31, 249-262.	4.0	12
56	Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study. British Journal of Cancer, 2020, 123, 1370-1376.	6.5	11
57	Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: pooled data from three independent cohorts. Clinical and Translational Oncology, 2019, 21, 1108-1111.	2.5	10
58	Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. Oncotarget, 2017, 8, 35193-35204.	1.9	10
59	Safety of palliative chemotherapy in advanced pancreatic cancer. Expert Opinion on Drug Safety, 2016, 15, 947-954.	2.5	9
60	Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer. Journal of Gastrointestinal Surgery, 2017, 21, 1775-1783.	2.1	9
61	Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. Clinical and Translational Oncology, 2021, 23, 2394-2401.	2.5	9
62	Quantitative Imaging Biomarkers of the Whole Liver Tumor Burden Improve Survival Prediction in Metastatic Pancreatic Cancer. Cancers, 2021, 13, 5732.	3.8	8
63	Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104. Acta Oncologica, 2015, 54, 993-1000.	1.8	7
64	High-Throughput Screening Identified Inherited Genetic Variations in the EGFR Pathway Contributing to Skin Toxicity of EGFR Inhibitors. Pharmacogenomics, 2015, 16, 1605-1619.	1.4	7
65	Improving post-surgical management of resected pancreatic cancer. Lancet, The, 2017, 390, 847-848.	12.1	7
66	Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. JNCI Cancer Spectrum, 2020, 4, pkz060.	2.8	7
67	Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer. JNCI Cancer Spectrum, 2022, 6, .	2.8	7
68	The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer. International Journal of Cancer, 2022, 151, 914-919.	5.4	6
69	High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood. Biomedicines, 2022, 10, 2405.	3.3	6
70	ALK expression is absent in pancreatic ductal adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1625-1628.	2.6	5
71	Translational Research in Pancreatic Cancer. Pancreas, 2014, 43, 150-152.	1.1	5
72	Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course. Annals of Oncology, 2017, 28, 438-439.	1.3	5

#	ARTICLE	IF	CITATIONS
73	Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate. <i>European Journal of Cancer</i> , 2018, 95, 109-111.	2.9	5
74	Neoadjuvant chemoradiation for esophageal cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 435-443.	2.2	5
75	TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer. <i>British Journal of Cancer</i> , 2023, 129, 175-182.	6.5	4
76	Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult. <i>British Journal of Cancer</i> , 2014, 111, 1675-1676.	6.5	3
77	Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN- γ , TNF- α and PD-1/PD-L1 in comparison to established serum tumor markers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2463-2474.	2.6	3
78	Comment on: "Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis". <i>Annals of Surgery</i> , 2022, 276, e1123-e1124.	4.4	2
79	Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia. <i>Infection</i> , 2023, 51, 231-238.	5.2	2
80	External Validation of 2 Prognostic Indices for Patients With Advanced Pancreatic Cancer Treated With First-line Therapy. <i>Pancreas</i> , 2012, 41, 738-744.	1.1	1
81	Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research. <i>BMC Cancer</i> , 2017, 17, 374.	2.6	1
82	Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood. <i>Biomedicines</i> , 2022, 10, 2534.	3.3	1
83	Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group. <i>ESMO Open</i> , 2024, 9, 102944.	4.3	1
84	Molekular-basierte Therapiekonzepte beim fortgeschrittenen Pankreaskarzinom. <i>Deutsche Medizinische Wochenschrift</i> , 2007, 132, 818-822.	0.2	0
85	Reply to: The definition of locally advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2010, 102, 1308-1308.	6.5	0
86	Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTH TM) Methodology: A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer. <i>Current Oncology</i> , 2023, 30, 5828-5834.	2.3	0